However, if epigenetic mechanisms play a major role in the oncogenesis of synovial sarcomas, the synergy of epigenetic drugs with ICI should be assessed in this tumor type, for example with an association of EZH2 inhibitors and ICI in tumors overexpressing EZH2. Here, EZH2 is linked to synovial sarcoma.